pharma · Hypertriglyceridemia · Asthma · GRCE
Grace Therapeutics
Grace Therapeutics is a pharma organization headquartered in Laval, CA. It trades on NYSE under ticker GRCE. Primary therapeutic focus areas include Hypertriglyceridemia, Asthma, Pain, Superficial Basal Cell Carcinoma, S
3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA HQ
18 Employees
Public company Type
GRCE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA
- Employees
- 18
- Programs
- 29
- Drugs
- 37
- Patents
- 34
GS-100
Phase 3 · gene therapy · NGLY1 Deficiency
GS-100 for NGLY1 Deficiency is a Phase 3 program (gene_therapy) at Grace Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code GS-100-A301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Grace Therapeutics
- Phase
- Phase 3
- Modality
- gene_therapy
- Indication
- NGLY1 Deficiency
- Status
- active
- Trials
- 1